A Phase I Study of Binimetinib in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Binimetinib (Primary) ; Pexidartinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions
- 29 Apr 2021 Status changed from discontinued to completed.
- 13 Apr 2020 Planned End Date changed from 1 Apr 2020 to 1 Apr 2021.
- 13 Apr 2020 Planned primary completion date changed from 1 Apr 2020 to 1 Apr 2021.